SCOTUS Myriad Genetics decision a significant shift from status quo

In the Association for Molecular Pathology v. Myriad Genetics decision, the Supreme Court unanimously held that naturally occurring DNA sequences are “products of nature” and therefore cannot be patented. “The Court’s holding represents a significant shift form the status quo,” says Kevin Emerson Collins, JD, patent law expert and professor of law at Washington University in St. Louis. “It reverses both the lower court and twenty years of precedent at the United States Patent and Trademark Office.